Evidence map›Paper›PMID 38830664›Full record

ArticleSaudi medical journal2024

Prevalence of CEA, CA 125, and CA 15-3 serum tumour markers in different regions of Saudi Arabia.

Abrar Ashi, Marwan Al-Hajeili, Sarah Almaghrabi, Jaudah Al-Maghrabi, Nora Trabulsi, Shmoukh Alghuraibi, Rawaih Alsiary, Nuha Alrayes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abrar AshiFrom the Department of Medical Laboratory Sciences (Ashi, Almaghrabi, Alrayes), Faculty of Applied Medical Sciences; from the Regenerative Medicine Unit (Ashi), King Fahd Medical Research Center; from the Center of Innovations in Personalized Medicine (Almaghrabi); from the Department of Medicine (Al-Hajeili); from the Department of Pathology (Al-Maghrabi); from the Department of Surgery (Trabulsi), Faculty of Medicine, King Abdulaziz University, from King Abdullah International Medical Research Centre (Alsiary), King Saud bin Abdulaziz University for Health Sciences, and from the Research and Development Unit (Alghuraibi), Al Borg Medical Laboratories, Al Borg Diagnostics, Jeddah, Kingdom of Saudi Arabia.ORCID https://orcid.org/0000-0003-3828-040X
Marwan Al-HajeiliFrom the Department of Medical Laboratory Sciences (Ashi, Almaghrabi, Alrayes), Faculty of Applied Medical Sciences; from the Regenerative Medicine Unit (Ashi), King Fahd Medical Research Center; from the Center of Innovations in Personalized Medicine (Almaghrabi); from the Department of Medicine (Al-Hajeili); from the Department of Pathology (Al-Maghrabi); from the Department of Surgery (Trabulsi), Faculty of Medicine, King Abdulaziz University, from King Abdullah International Medical Research Centre (Alsiary), King Saud bin Abdulaziz University for Health Sciences, and from the Research and Development Unit (Alghuraibi), Al Borg Medical Laboratories, Al Borg Diagnostics, Jeddah, Kingdom of Saudi Arabia.
Sarah AlmaghrabiFrom the Department of Medical Laboratory Sciences (Ashi, Almaghrabi, Alrayes), Faculty of Applied Medical Sciences; from the Regenerative Medicine Unit (Ashi), King Fahd Medical Research Center; from the Center of Innovations in Personalized Medicine (Almaghrabi); from the Department of Medicine (Al-Hajeili); from the Department of Pathology (Al-Maghrabi); from the Department of Surgery (Trabulsi), Faculty of Medicine, King Abdulaziz University, from King Abdullah International Medical Research Centre (Alsiary), King Saud bin Abdulaziz University for Health Sciences, and from the Research and Development Unit (Alghuraibi), Al Borg Medical Laboratories, Al Borg Diagnostics, Jeddah, Kingdom of Saudi Arabia.
Jaudah Al-MaghrabiFrom the Department of Medical Laboratory Sciences (Ashi, Almaghrabi, Alrayes), Faculty of Applied Medical Sciences; from the Regenerative Medicine Unit (Ashi), King Fahd Medical Research Center; from the Center of Innovations in Personalized Medicine (Almaghrabi); from the Department of Medicine (Al-Hajeili); from the Department of Pathology (Al-Maghrabi); from the Department of Surgery (Trabulsi), Faculty of Medicine, King Abdulaziz University, from King Abdullah International Medical Research Centre (Alsiary), King Saud bin Abdulaziz University for Health Sciences, and from the Research and Development Unit (Alghuraibi), Al Borg Medical Laboratories, Al Borg Diagnostics, Jeddah, Kingdom of Saudi Arabia.
Nora TrabulsiFrom the Department of Medical Laboratory Sciences (Ashi, Almaghrabi, Alrayes), Faculty of Applied Medical Sciences; from the Regenerative Medicine Unit (Ashi), King Fahd Medical Research Center; from the Center of Innovations in Personalized Medicine (Almaghrabi); from the Department of Medicine (Al-Hajeili); from the Department of Pathology (Al-Maghrabi); from the Department of Surgery (Trabulsi), Faculty of Medicine, King Abdulaziz University, from King Abdullah International Medical Research Centre (Alsiary), King Saud bin Abdulaziz University for Health Sciences, and from the Research and Development Unit (Alghuraibi), Al Borg Medical Laboratories, Al Borg Diagnostics, Jeddah, Kingdom of Saudi Arabia.
Shmoukh AlghuraibiFrom the Department of Medical Laboratory Sciences (Ashi, Almaghrabi, Alrayes), Faculty of Applied Medical Sciences; from the Regenerative Medicine Unit (Ashi), King Fahd Medical Research Center; from the Center of Innovations in Personalized Medicine (Almaghrabi); from the Department of Medicine (Al-Hajeili); from the Department of Pathology (Al-Maghrabi); from the Department of Surgery (Trabulsi), Faculty of Medicine, King Abdulaziz University, from King Abdullah International Medical Research Centre (Alsiary), King Saud bin Abdulaziz University for Health Sciences, and from the Research and Development Unit (Alghuraibi), Al Borg Medical Laboratories, Al Borg Diagnostics, Jeddah, Kingdom of Saudi Arabia.
Rawaih AlsiaryFrom the Department of Medical Laboratory Sciences (Ashi, Almaghrabi, Alrayes), Faculty of Applied Medical Sciences; from the Regenerative Medicine Unit (Ashi), King Fahd Medical Research Center; from the Center of Innovations in Personalized Medicine (Almaghrabi); from the Department of Medicine (Al-Hajeili); from the Department of Pathology (Al-Maghrabi); from the Department of Surgery (Trabulsi), Faculty of Medicine, King Abdulaziz University, from King Abdullah International Medical Research Centre (Alsiary), King Saud bin Abdulaziz University for Health Sciences, and from the Research and Development Unit (Alghuraibi), Al Borg Medical Laboratories, Al Borg Diagnostics, Jeddah, Kingdom of Saudi Arabia.
Nuha AlrayesFrom the Department of Medical Laboratory Sciences (Ashi, Almaghrabi, Alrayes), Faculty of Applied Medical Sciences; from the Regenerative Medicine Unit (Ashi), King Fahd Medical Research Center; from the Center of Innovations in Personalized Medicine (Almaghrabi); from the Department of Medicine (Al-Hajeili); from the Department of Pathology (Al-Maghrabi); from the Department of Surgery (Trabulsi), Faculty of Medicine, King Abdulaziz University, from King Abdullah International Medical Research Centre (Alsiary), King Saud bin Abdulaziz University for Health Sciences, and from the Research and Development Unit (Alghuraibi), Al Borg Medical Laboratories, Al Borg Diagnostics, Jeddah, Kingdom of Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo study the prevalence of tumor marker (TM) carcinoembryonic antigen (CEA), cancer antigen 125 (CA 125), and cancer antigen 15-3 (CA 15-3) levels in the Saudi population, based on gender, age, and demographic region, and whether the patients were referred by a hospital or self-referred.

methodsRetrospective analysis was carried out on 7,019 samples gathered from the Western, Northern, Central, Southern, and Eastern regions of Saudi Arabia between 2021-2022. The TMs were categorized into normal and abnormal levels, according to the reference ranges. Statistical analysis was carried out to assess the relations between variants (age groups, gender, and demographic regions) using the Chi-square test, and their correlations were assessed using Spearman's test.

resultsAmong all patients, CEA, CA 125, and CA 15-3 levels were found to be significantly correlated with age (

conclusionIncreased levels of CEA, CA 125, and CA 15-3 TMs in the study population were significantly correlated with age. The CEA and CA 15-3 levels were within the normal range, while CA 125 levels were above the normal range in the older male population. These results suggest that the utilization of such TMs is age dependent and would have validity if applied with other parameters.

Indexed as

Biomarkers, TumorCA-125 AntigenCarcinoembryonic AntigenMucin-1AdolescentAdultAgedAged, 80 and overAge FactorsChildFemaleHumansMaleMiddle AgedPrevalenceRetrospective StudiesBiomarkers, TumorCA-125 AntigenCarcinoembryonic AntigenMucin-1CA 125CA 15-3CEAserum tumour markers

Identifiers

PMID38830664
PMCPMC11147600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.